O
10.27
-0.85 (-7.64%)
| Previous Close | 11.12 |
| Open | 11.06 |
| Volume | 3,236,189 |
| Avg. Volume (3M) | 3,622,518 |
| Market Cap | 2,187,997,696 |
| Price / Sales | 26.47 |
| Price / Book | 7.02 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Operating Margin (TTM) | -597.47% |
| Diluted EPS (TTM) | -1.11 |
| Quarterly Revenue Growth (YOY) | -27.60% |
| Total Debt/Equity (MRQ) | 28.66% |
| Current Ratio (MRQ) | 10.22 |
| Operating Cash Flow (TTM) | -145.46 M |
| Levered Free Cash Flow (TTM) | -87.96 M |
| Return on Assets (TTM) | -27.21% |
| Return on Equity (TTM) | -57.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Ocular Therapeutix, Inc. | Bullish | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.25 |
|
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 3.82% |
| % Held by Institutions | 87.01% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Summer Road Llc | 30 Sep 2025 | 12,579,657 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 21.00 (HC Wainwright & Co., 104.48%) | Buy |
| 21.00 (Chardan Capital, 104.48%) | Buy | |
| Median | 21.00 (104.48%) | |
| Low | 20.00 (Needham, 94.74%) | Buy |
| Average | 20.67 (101.27%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 16.06 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 09 Dec 2025 | 21.00 (104.48%) | Buy | 15.95 |
| 05 Nov 2025 | 21.00 (104.48%) | Buy | 10.81 | |
| HC Wainwright & Co. | 08 Dec 2025 | 21.00 (104.48%) | Buy | 16.11 |
| 25 Nov 2025 | 19.00 (85.00%) | Buy | 12.13 | |
| Needham | 08 Dec 2025 | 20.00 (94.74%) | Buy | 16.11 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights |
| 23 Jan 2026 | Announcement | Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 21 Jan 2026 | Announcement | Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer |
| 08 Dec 2025 | Announcement | Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD |
| 05 Dec 2025 | Announcement | Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 24 Nov 2025 | Announcement | Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR |
| 12 Nov 2025 | Announcement | Ocular Therapeutix™ to Participate in November and December Investor Conferences |
| 07 Nov 2025 | Announcement | Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |